医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

2021年01月11日 PM09:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan & CAMBRIDGE, Mass.

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are invited to listen to the live webcast with Christophe Weber, president and chief executive officer, here. A replay of the webcast will also be archived at the same location. A link to the webcast and slides for download will also be available on Takeda’s website at https://www.takeda.com/investors/ir-events/.

ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005289/en/

CONTACT

Media Contacts:

Japanese Media

Kazumi Kobayashi

kazumi.kobayashi@takeda.com

+81 (0) 3-3278-2095

Media Outside Japan

Holly Campbell

holly.campbell@takeda.com

+1 617-588-9013

Investor Relations:

Christopher O’Reilly

christopher.oreilly@takeda.com

+81 (0) 3-3278-2543

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • LUCA Science and Kyowa Kirin Announce Joint Research Agreement on Mitochondrial Disease Treatment With Novel Mitochondria Modality
  • すい臓疾患検出用の革新的なAIソフトウエアのヒト初回適用が成功
  • “Everyday Japan Expo” Melo Became Brand New Sterilized Retail Shop in Singapore.
  • 【日本企業唯一】3歳未満向けの乳幼児用食品に使用が認められたプロバイオティクス※1 『ビフィズス菌BB536』が中国「新食品原料」に登録※2
  • City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors